Proteasome Inhibitors Block Ikaros Degradation by Lenalidomide in Multiple Myeloma

Haematologica - Italy
doi 10.3324/haematol.2015.124297
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Proteasome Inhibitors Block Myeloma-Induced Osteocyte Death in Vitro and in Vivo in Multiple Myeloma Patients

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Lenalidomide Induced Stroke in Multiple Myeloma

Clinical Practice
MedicinePharmacology
2016English

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma

Pharmaceuticals
Molecular MedicinePharmaceutical Science
2014English

MAFb Protein Confers Intrinsic Resistance to Proteasome Inhibitors in Multiple Myeloma

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Lenalidomide Combined With Low-Dose Cyclophosphamide and Prednisone Modulates Ikaros and Aiolos in Lymphocytes, Resulting in Immunostimulatory Effects in Lenalidomide-Refractory Multiple Myeloma Patients

Oncotarget
Oncology
2018English

Novel Strategies in the Treatment of Multiple Myeloma: From Proteasome Inhibitors to Immunotherapy

Journal of Cell Science & Therapy
2010English

Proteasome and Heat Shock Protein 70 (HSP70) Inhibitors as Therapeutic Alternative in Multiple Myeloma

Oncotarget
Oncology
2017English

Endoplasmic-Reticulum Stress Pathway-Associated Mechanisms of Action of Proteasome Inhibitors in Multiple Myeloma

International Journal of Hematology
Hematology
2016English

Design, Synthesis, and Biological Evaluation of Bone-Targeted Proteasome Inhibitors for Multiple Myeloma

Bioorganic and Medicinal Chemistry Letters
Organic ChemistryMolecular MedicineMolecular BiologyBiochemistryClinical BiochemistryPharmaceutical ScienceDrug Discovery
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy